Thomas Burmeister - Concepedia

Author

Thomas Burmeister

Charité - Universitätsmedizin Berlin ORCID

Also Known As

Burmeister Thomas, Burmeister, Thomas, Gröger, D, T Burmeister, T. Burmeister, Thomas Burmeister, Thomas Burmeister (276604)

171

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Goethe University Frankfurt University Hospital Schleswig-Holstein University of Lübeck Heidelberg University

About

Thomas Burmeister is an author at Charité - Universitätsmedizin Berlin specializing in medicine, pathology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	26	2K
2	Health Sciences	4	4	197
3	Natural Sciences	1	1	11
4	Allergy	1	1	18
5	Allergy Medicine	1	1	18

Thomas Burmeister

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival Max S. Topp, Peter Kufer, Nicola Gökbuget, Journal of Clinical Oncology	2011	902
The MLL recombinome of acute leukemias in 2017 Claus Meyer, Thomas Burmeister, Daniela Gröger, Leukemia	2017	670
The MLL recombinome of acute leukemias in 2013 Claus Meyer, Jörg Hofmann, Thomas Burmeister, Leukemia	2013	506
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Blood	2012	466
New insights to the MLL recombinome of acute leukemias Claus Meyer, Eric Kowarz, Jörg Hofmann, Leukemia Hematological MalignancyMixed-phenotype Acute LeukemiaHematologyNew InsightsMedicine	2009	410
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial Dieter Hoelzer, Jan Walewski, Hartmut Döhner, Blood	2014	296
The MLL recombinome of acute leukemias Claus Meyer, Björn Schneider, Stephan M. Jakob, Leukemia Hematological MalignancyMixed-phenotype Acute LeukemiaHematologyMll RecombinomeMedicine	2006	275
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia Wolfgang Bethge, Jolanta Dengler, M Bornhäuser, Leukemia Hematological MalignancyTransplantationMedicineMixed-phenotype Acute LeukemiaImmunology	2012	228
The KMT2A recombinome of acute leukemias in 2023 Claus Meyer, Patrizia Larghero, Bruno A. Lopes, Leukemia	2023	192
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts Olga Blau, Claudia D. Baldus, Wolf‐Karsten Hofmann, Blood	2011	168

Page 1